ABORTION PILL ACCESS and other reproductive services will have another contentious year in 2026 across state legislatures as the Trump administration is expected to slow-walk further action.
- Criminalization of providers, reclassifying abortion drugs as controlled substances, and in-person dispensing requirements are among the issues percolating in legislatures across the US.
- The Trump administration has yet to deliver on a long-awaited mifepristone safety study that could upend availability of the abortion pill, paving the way for legislatures to take a greater role in reining in reproductive services within their borders.
- Most states launch their legislative sessions at the beginning ...